This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment of drug-resistant tuberculosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

treatment of multi drug resistant tuberculosis

Seek expert advice

In 2013, out of the reported 136,000 MDR-TB patients, just over 71% (97,000) started on treatment. This is a three-fold increase compared with 2009 (1).

Access to quality-assured drug susceptibility testing (DST) is a critical component of TB treatment. Furthermore it is important that drug resistant TB programmes to have knowledge about:

  • the prevalence of drug resistance in new patients, as well as in different groups of retreatment cases
  • which and with what frequency second-line anti-TB drugs have been used within a given area served by a programmatic strategy

Treatment strategies for MDR-TB can be

  • standardised
    • data on historical resistance patterns and drugs which have been used in that region are used as the basis for regimen design
    • all patients in a defined group or category receive the same regimen
    • suspected MDR-TB should be confirmed by DST whenever possible
  • individualized
    • each regimen is designed based on the patient's past history of TB treatment and individual DST results (1,2)

Current recommendation requires 18-24 months of treatment for MDR-TB (2).

  • empiric standardized regimens often need to be adjusted based on patient clinical history, once additional history or when DST results becomes available
  • individual regimens are designed based on DST of the infecting strain, patient's history of TB treatment and contact history.

The following steps can be uses to build a regimen for drug-resistant TB treatment.

  • step 1 - choose an injectable agent such as amikacin, kanamycin, or capreomycin
    • Streptomycin is generally not used because of high rates of resistance in patients with MDR-TB
  • step 2 - choose a higher generation fluoroquinolone
    • use a later generation fluoroquinolone. If levofloxacin (or ofloxacin) resistance is documented, use moxifloxacin
    • avoid moxifloxacin if possible when using bedaquiline or delamanid
  • step3 - choose two or more oral bacteriostatic second-line anti-TB drugs
    • e.g. - Cycloserine/terizidone, Para-aminosalicylic acid (PAS), Ethionamide/prothionamide
    • Ethionamide/prothionamide is considered the most effective
    • DST is not considered reliable for the drugs in this group
  • step 4 - Add Group 1 drugs. Pyrazinamide, Ethambutol
    • Pyrazinamide is routinely added in most regimens
  • step 5 - consider adding a new antituberculosis drug
    • e.g. - Bedaquiline, Delamanid, Linezolid, Clofazimine
    • consider if four second-line anti-TB drugs are not likely to be effective
    • if drugs are needed from this group, it is recommended to add two or more

Treatment of MDR-TB can be divided into:

  • intensive phase
    • consist of at least four second-line anti-TB drugs that are likely to be effective (including an injectable anti-TB drug), as well as pyrazinamide
    • lasts at least eight months in total, but the duration can be modified according to the patient's response to treatment
  • continuation phase
    • continuation of treatment with other drugs

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.